Enhanced binding of nor-binaltorphimine to κ-opioid receptors in rats dependent on butorphanol

Journal of Neuroscience Research

Volumn 72, Issue 6, 2003, Pages 781-789

  Fan, Lir Wan ^a   Tien, Lu Tai ^a   Tanaka, Sachiko ^b   Sasaki, Kenro ^a   Park, Younjoo ^c   Ma, Tangeng ^a   Rockhold, Robin William ^a   Ho, Ing Kang ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b SHOWA UNIVERSITY   (Japan)

^c National Institute of Toxicological Research   (South Korea)

Author keywords

1 and 2 opioid receptors; Autoradiography; Butorphanol dependence; Butorphanol withdrawal; Competitive binding; Nor binaltorphimine

Indexed keywords

BREMAZOCINE; BUTORPHANOL; ENADOLINE; ENKEPHALIN[2 DEXTRO ALANINE 4 METHYLPHENYLALANINE 5 GLYCINE]; ENKEPHALIN[2,5 DEXTRO PENICILLAMINE]; KAPPA 1 OPIATE RECEPTOR; KAPPA 2 OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; N METHYL N [7 (1 PYRROLIDINYL) 1 OXASPIRO[4.5]DEC 8 YL]BENZENEACETAMIDE; NORBINALTORPHIMINE; UNCLASSIFIED DRUG;

AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTORADIOGRAPHY; BINDING AFFINITY; CAUDATE NUCLEUS; CLAUSTRUM; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG RECEPTOR BINDING; DRUG WITHDRAWAL; FRONTAL CORTEX; HIPPOCAMPUS; HYPOTHALAMUS NUCLEUS; IC 50; LOCUS CERULEUS; NONHUMAN; NUCLEUS ACCUMBENS; PARIETAL LOBE; PERIAQUEDUCTAL GRAY MATTER; PRIORITY JOURNAL; PUTAMEN; PYRIFORM CORTEX; RAT; RECEPTOR SENSITIVITY; SUBSTANTIA NIGRA; SUPERIOR COLLICULUS; THALAMUS NUCLEUS; VENTRAL TEGMENTUM;

ANIMALS; BRAIN; BUTORPHANOL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NALTREXONE; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, OPIOID, KAPPA; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 0037982417     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/jnr.10578     Document Type: Article

References (47)

1. Alcaraz C, Milanes MV, Vargas ML. 1993. Chronic kappa opioid receptor antagonism produces supersensitivity to U-50,488H at the hypothalamopituitary-adrenocortical (HPA) axis level. J Pharmacol Exp Ther 266:1385-1389.
2. Brown GR. 1985. Stadol dependence: another case. JAMA 254:910.
3. Chang KJ, Wei ET, Killian A, Chang JK. 1983. Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther 227:403-408.
4. Dobkin AB, Arandia HY, Byles PH, Africa BF, Caruso FS, Noveck RJ. 1976. Butorphanol tartrate: 2. Safety and efficacy in balanced anaesthesia. Can Anaesth Soc J 23:601-608.
5. Evans WS, Bowen JN, Giordano FL, Clark B. 1985. A case of stadol dependence. JAMA 253:2191-2192.
6. 2-opioid receptor binding in the brain during butorphanol dependence and withdrawal in rats. Soc Neurosci Abstr 26:773.3.
7. Fan LW, Tanaka S, Tien LT, Ma T, Sasaki K, Chudapongse N, Rockhold RW, Ho IK. 2001. Characterization of kappa1-opioid receptors in various anatomical regions of the brain of butorphanol dependent rats. Soc Neurosci Abstr 27:223.6.
8. 1opioid receptor binding in the rat brain. Brain Res Bull 58:149-160.
9. Feng YZ, Rockhold RW, Ho IK. 1997. Nor-binaltorphimine precipitates withdrawal and excitatory amino acid release in the locus ceruleus of butorphanol but not morphine-dependent rats. J Pharmacol Exp Ther 283:932-938.
10. Hjorth SA, Thirstrup K, Grandy DK, Schwartz TW. 1995. Analysis of selective binding epitopes for the kappa-opioid receptor antagonist norbinaltorphimine. Mol Pharmacol 47:1089-1094.
11. Hjorth SA, Thirstrup K, Schwartz TW. 1996. Radioligand-dependent discrepancy in agonist affinities enhanced by mutations in the kappaopioid receptor. Mol Pharmacol 50:977-984.
12. Ho IK, Feng YZ, Tokuyama S, Hoshi K, Rockhold RW. 1997. Glutamate in opioid dependence. Nihon Shinkei Seishin Yakurigaku Zasshi 17:175-180.
13. Horan P, Ho IK. 1991. The physical dependence liability of butorphanol: a comparative study with morphine. Eur J Pharmacol 203:387-391.
14. Hoshi K, Ma T, Oh S, Ho IK. 1997. Increased release of excitatory amino acids in rat locus coeruleus in kappa-opioid agonist dependent rats precipitated by nor-binaltorphimine. Brain Res 753:63-68.
15. Jaw SP, Hoskins B, Ho IK. 1993a. Opioid antagonists and butorphanol dependence. Pharmacol Biochem Behav 44:497-500.
16. Jaw SP, Makimura M, Hoskins B, Ho IK. 1993b. Effects of norbinaltorphimine on butorphanol dependence. Eur J Pharmacol 239:133-140.
17. Jaw SP, Makimura M, Oh KW, Hoskins B, Ho IK. 1994. Involvement of kappa-opioid receptors in opioid dependence/withdrawal: studies using butorphanol. Eur J Pharmacol 257:153-160.
18. Koob GF, Maldonado R, Stinus L. 1992. Neural substrates of opiate withdrawal. Trends Neurosci 15:186-191.
19. Krupnick JG, Benovic JL. 1998. The role of receptor kinases and arrestins in G protein-coupled receptor regulation. Annu Rev Pharmacol Toxicol 38:289-319.
20. Larson DL, Jones RM, Hjorth SA, Schwartz TW, Portoghese PS. 2000. Binding of norbinaltorphimine (norBNI) congeners to wild-type and mutant mu and kappa opioid receptors: molecular recognition loci for the pharmacophore and address components of kappa antagonists. J Med Chem 43:1573-1576.
21. Law PY, Wong YH, Loh HH. 1999. Mutational analysis of the structure and function of opioid receptors. Biopolymers 51:440-455.
22. Li JG, Benovic JL, Liu-Chen LY. 2000. Mechanisms of agonist-induced down-regulation of the human κ-opioid receptor: internalization is required for down-regulation. Mol Pharmacol 58:795-801.
23. Liu N, Ho IK, Rockhold RW. 1999. Contribution of glutamatergic systems in locus coeruleus to nucleus paragigantocellularis stimulation-evoked behavior. Pharmacol Biochem Behav 63:555-567.
24. Meng F, Hoversten MT, Thompson RC, Taylor L, Watson SJ, Akil H. 1995. A chimeric study of the molecular basis of affinity and selectivity of the kappa and the delta opioid receptors. Potential role of extracellular domains. J Biol Chem 270:12730-12736.
25. Meng F, Ueda Y, Hoversten MT, Thompson RC, Taylor L, Watson SJ, Akil H. 1996. Mapping the receptor domains critical for the binding selectivity of delta-opioid receptor ligands. Eur J Pharmacol 311:285-292.
26. Millan MJ, Morris BJ, Herz A. 1988. Antagonist-induced opioid receptor up-regulation. I. Characterization of supersensitivity to selective mu and kappa agonists. J Pharmacol Exp Ther 247:721-728.
27. Nestler EJ. 1997. Molecular mechanisms of opiate and cocaine addiction. Curr Opin Neurobiol 7:713-719.
28. Nijssen PC, Childers SR. 1987. Characteristics of sodium-induced increase in opiate antagonist binding sites in rat brain membranes. Eur J Pharmacol 135:355-364.
29. 35S]GTPgammaS binding in butorphanol continuously infused rat. Brain Res Bull 52:17-20.
30. Paxinos G, Watson C. 1998. The rat brain in stereotaxic coordinates, 4th ed. San Diego: Academic Press.
31. Peachey JE. 1987. Clinical observations of agonist-antagonist analgesic dependence. Drug Alcohol Depend 20:347-365.
32. Pircio AW, Gylys JA, Cavanagh RL, Buyniski JP, Bierwagen ME. 1976. The pharmacology of butorphanol, a 3,14-dihydroxymorphinan narcotic antagonist analgesic. Arch Int Pharmacodyn Ther 220:231-257.
33. Pogozheva ID, Lomize AL, Mosberg HI. 1997. The transmembrane 7-alpha-bundle of rhodopsin: distance geometry calculations with hydrogen bonding constraints. Biophys J 72:1963-1985.
34. Pogozheva ID, Lomize AL, Mosberg HI. 1998. Opioid receptor threedimensional structures from distance geometry calculations with hydrogen bonding constraints. Biophys J 75:612-634.
35. Redmond DE Jr, Krystal JH. 1984. Multiple mechanisms of withdrawal from opioid drugs. Annu Rev Neurosci 7:443-478.
36. Rockhold RW, Liu N, Coleman D, Commiskey S, Shook J, Ho IK. 2000. The nucleus paragigantocellularis and opioid withdrawal-like behavior. J Biomed Sci 7:270-276.
37. Roth BL, Willins DL, Kroeze WK. 1998. G protein-coupled receptor (GPCR) trafficking in the central nervous system: relevance for drugs of abuse. Drug Alcohol Depend 51:73-85.
38. Stevens CW, Lacey CB, Miller KE, Elde RP, Seybold VS. 1991. Biochemical characterization and regional quantification of mu, delta and kappa opioid binding sites in rat spinal cord. Brain Res 550:77-85.
39. Unterwald EM, Knapp C, Zukin RS. 1991. Neuroanatomical localization of kappa 1 and kappa 2 opioid receptors in rat and guinea pig brain. Brain Res 562:57-65.
40. Way EL, Loh HH, Shen FH. 1969. Simultaneous quantitative assessment of morphine tolerance and physical dependence. J Pharmacol Exp Ther 167:1-8.
41. Williams JT, Christie MJ, Manzoni O. 2001. Cellular and synaptic adaptations mediating opioid dependence. Physiol Rev 81:299-343.
42. Wongchanapai W, Tsang BK, He Z, Ma T, Ho IK. 1998. Supersensitivity of spinal opioid receptors to antagonists in intrathecal butorphanol and morphine dependence. Life Sci 63:2175-2180.
43. Xue JC, Chen C, Zhu J, Kunapuli S, DeRiel JK, Yu L, Liu-Chen LY. 1994. Differential binding domains of peptide and non-peptide ligands in the cloned rat kappa opioid receptor. J Biol Chem 269:30195-30199.
44. Yoburn BC, Shah S, Chan K, Duttaroy A, Davis T. 1995. Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. Pharmacol Biochem Behav 51:535-539.
45. Zhu H, Rockhold RW, Ho IK. 1998a. The role of glutamate in physical dependence on opioids. Jpn J Pharmacol 76:1-14.
46. Zhu J, Luo LY, Mao GF, Ashby B, Liu-Chen LY. 1998b. Agonist-induced desensitization and down-regulation of the human kappa opioid receptor expressed in Chinese hamster ovary cells. J Pharmacol Exp Ther 285:28-36.
47. Zukin RS, Eghbali M, Olive D, Unterwald EM, Tempel A. 1988. Characterization and visualization of rat and guinea pig brain kappa opioid receptors: evidence for kappa 1 and kappa 2 opioid receptors. Proc Natl Acad Sci USA 85:4061-4065.